Xeris Biopharma Holdings (XERS) Payables (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Payables came in at $11.5 million in Q1 2026, up 80.53% YoY from $6.4 million in Q1 2025, and up 272.79% on a QoQ basis from $3.1 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Payables (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Payables data on file, last reported at $11.5 million in Q1 2026.
- Quarterly Payables rose 80.53% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 80.53% YoY) and the FY2025 annual result came in at $3.1 million, up 34.32% from the prior year.
- Payables advanced to $11.5 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $12.1 million in Q3 2023 to a low of $2.3 million in Q4 2024.
- A 5-year average of $7.8 million and a median of $7.1 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables soared 208.43% — and 2024, when it sank 80.2%.
- Tracing XERS's Payables over 5 years: stood at $4.6 million in 2022, then jumped by 151.09% to $11.6 million in 2023, then slumped by 80.2% to $2.3 million in 2024, then soared by 34.32% to $3.1 million in 2025, then jumped by 272.79% to $11.5 million in 2026.
- The last three Payables figures came in at $11.5 million (Q1 2026), $3.1 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -7.73 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 986.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 9.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.34 Mn |
| Mar 31, 2026 | 11.47 Mn |
| Dec 31, 2025 | 3.08 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 9.46 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 11.57 Mn |
| Sep 30, 2023 | 12.08 Mn |
| Jun 30, 2023 | 11.62 Mn |
| Mar 31, 2023 | 11.98 Mn |
| Dec 31, 2022 | 4.61 Mn |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 6.63 Mn |
| Mar 31, 2022 | 11.09 Mn |
| Dec 31, 2021 | 8.92 Mn |
| Sep 30, 2021 | 4.29 Mn |